Updated:
HLB
HLB was established in 1985 by Jin Yang-gon. The firm began as a corporate entity and expanded into biopharmaceutical development and manufacturing.
HLB
HLB was established in 1985 by Jin Yang-gon. The firm began as a corporate entity and expanded into biopharmaceutical development and manufacturing. HLB allocates across biotechnology and pharmaceuticals through direct ownership and early-stage investments. Confirmed holdings include Elevar Therapeutics, Immunomic Therapeutics, and Verismo Therapeutics. The firm also holds positions in listed affiliates such as HLB Life Science and HLB Pharmaceutical. Activity spans South Korea and the United States, with manufacturing facilities in Ulsan and Osong. The group reports no public professional count. It maintains offices in Seoul and Sejong in addition to the Ulsan headquarters. HLB Foundation operates as the philanthropic vehicle focused on health initiatives in South Korea. May 2024: Presented clinical trial results at the ASCO Annual Meeting. HLB controls its subsidiaries through 100 percent ownership stakes executed via dedicated entities such as HLB USA and HLB Innovation. This direct ownership model distinguishes the group from fund-based investors and ties capital deployment to operational control of portfolio companies.
General information
Firm type
Corporate Investor
Year founded
1985
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Ulsan
Corporate office
10-5 Myeonghaksandanseo-ro Yeondong-myeon, Ulsan, South Korea
Additional offices
Seoul · Sejong
Principals
Jin Yang-gon
Chairman
Sector focus
Frequently asked questions
Who runs investment decisions at HLB?
Jin Yang-gon serves as Chairman and founder. Kim Tae-han chairs the Bio Division.
Does HLB participate in fund commitments or only direct deals?
HLB executes through direct ownership of operating companies and early-stage investments rather than external fund commitments.
Which sectors does HLB explicitly avoid?
No explicit avoidance sectors are disclosed in available records.
Where does the underlying wealth come from?
Wealth origin is not publicly attributed to a specific family branch or industry outside the firm's own operations.
What is HLB's known posture on co-investments alongside external GPs?
No co-investment activity with external GPs is recorded.
How is HLB related to its US subsidiaries?
Elevar Therapeutics and Verismo Therapeutics are held at 100 percent through HLB USA and HLB Innovation respectively.
Does HLB maintain philanthropic structures, and how are they separated?
HLB Foundation operates separately with a focus on health and medical support in South Korea.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: